BACKGROUND: Alefacept blocks T-cell activation and induces apoptosis of memory T cells. It improves @entity1569 and may induce prolonged remissions. Experience with alefacept in @entity5515 ( @entity5515 ) is limited. OBJECTIVE: The objective of the study was to observe the effectiveness and safety of alefacept in the treatment of @entity5515 . METHODS: Alefacept was administered weekly for 16 weeks by intramuscular (IM) injection of 15 mg to 15 @entity1 with moderate to very severe @entity5515 . @entity1 were followed for an additional 12 weeks. RESULTS: Four weeks after 16 weeks of treatment, there was a 49.6% reduction in the @entity709 Psoriasis Area and Severity Index (PPPASI) and a 38.6% and a 64.5% reduction in total and fresh pustules, respectively. Eight weeks after dosing, 53.3% achieved PPPASI 50, 26.7% achieved PPPASI 75, and one @entity1 was clear. The mean percent reduction in total pustules and fresh pustules was 46.1% and 61.2%, respectively; 73% had no @entity158 , 53% had no itching, and 80% had no functional impairment. The @entity24734 responded better than the soles. CONCLUSIONS: This pilot showed that 16 weeks of once-weekly alefacept 15 mg IM was safe, led to improvement in @entity5515 in all 15 treated @entity1 , and induced a remission in one @entity1 . Larger double-blind studies are warranted.

Alefacept is safe and efficacious in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis vulgaris'] @entity709 :: ('MESH:D007645', 'Disease') :: ['Palmoplantar Pustulosis'] @entity24734 :: ('MESH:C535620', 'Disease') :: ['palms'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity5515 :: ('MESH:D017499', 'Disease') :: ['palmar plantar pustulosis', 'PPP']
@entity5515 :: (MESH:D017499,Disease) :: ['palmar plantar pustulosis']
